Name Lee Jin Soo Image File
Email jslee@ncc.re.kr
Specialty Thoracic/Head and Neck Medical Oncology

Image File Education
196800 197000 Seoul National University College of Medicine Medicine Premedical Degree
197000 197400 Seoul National University College of Medicine Medicine M.D.
197400 197600 Seoul National University Graduate School of Public Health Public Health M.P.H.
197800 200700 Seoul National University Graduate School of Public Health Public Health Ph.D.

Image File Postgraduate & Faculty Appointments
197500 197600 Seoul National University Hospital; Seoul, Korea Rotating Internship
197600 197800 Geoje Community Health Center; Gyeongsangnam-do, Korea Head of the first medical deparment
197900 198200 St. Joseph Hospital; Chicago, Illinois Residency in Internal Medicine
198200 198400 University of Texas M. D. Anderson Cancer Center, Houston, Texas Medical Oncology Fellow
198400 198500 University of Texas M. D. Anderson Cancer Center; Department of Medical Oncology; Section of Thoracic Oncology; Houston, Texas Faculty Associate
198500 198700 University of Texas M. D. Anderson Cancer Center; Department of Medical Oncology; Section of Thoracic Oncology; Houston, Texas Assistant Internist and Instructor of Medicine
198700 199200 University of Texas M. D. Anderson Cancer Center; Department of Medical Oncology; Section of Thoracic Oncology; Houston, Texas Assistant Internist and Assistant Professor of Med
199200 199700 University of Texas M. D. Anderson Cancer Center; Department of Thoracic/Head and Neck Medical Oncology; Houston, Texas Associate Internist and Associate Professor
199700 200100 University of Texas M. D. Anderson Cancer Center; Department of Thoracic/Head and Neck Medical Oncology; Houston, Texas Internist and Professor of Medicine
200109 200409 National Cancer Center Hospital Director
200110 200302 Center for Lung Cancer, National Cancer Center Head
200110 200711 Lung Cancer Branch, National Cancer Center Cheif
200309 present University of Texas M. D. Anderson Cancer Center; Department of Thoracic/Head and Neck Medical Oncology; Houston, Texas Professor
200311 200709 The Organizing Committee of the 12th Conference, IASLC Chariman
200507 200709 The Board of Directors, IASLC Chairman
200605 200806 Research Institute, National Cancer Center Director
200607 present Korea Society of Epidemiology Chairman
200802 present Central Pharmaceutical Affairs Council Member
200806 201406 National Cancer Center President
201006 201106 Korea Cancer Association President
201403 201406 Graduate School of Cancer Science & Policy President

Image File Academic Activities
000000 present American Association for the Advanced of Science
000000 present American Associaton for Cancer Research
000000 present American Medical Association
000000 present American College of Physicians
000000 present American Society of Clinical Oncology
000000 present Harris County Medical Society
000000 present International Association for the Study of Lung Cancer
000000 present NCI Intergroup Working Cadre in Lung Cancer
000000 present International Association for the Study of Lung Cancer
000000 present Korea Cancer Association
000000 present International Society of Cancer Chemoprevention
000000 present Radiation Therapy Oncology Group
000000 present Texas Medical Association
000000 present American Society for Therapeutic Radiology and Oncology

Image File Social Activities
199100 200100 The Radication Therapy Oncology Group, Lung Cancer Committee and Medical Oncology Committee Member
199100 200100 Combined Chemoradiation Therapy Protocols RTOG91-06, RT0G92-04, RTOG94-10 Co-Chairman
199300 199300 The FDA-Initiated Public Conference on Penalist
199300 199500 Surveillance Commitee Alternative Member
199300 199400 Medical Practce Subcommittee of Executive Committee Medical Staff
199400 199800 The NCI Cancer Therapy Evaluation Program, Intergroup Working Cadre of Lung Cancer Member
199500 200100 Surveillance Committee(IRB) Member
199600 199600 Program Committee, The 8th World Conference on Lung Cancer, 1997, Dublin, Ireland Member
199600 199900 Institutional Research Support Committee Member
199900 200000 Clinical Research Day Organizing Committee Member
199900 200100 Credentials Committee of the Medical Sfaff Member
200100 present International Assocation for the Academic Study of Lung Cancer, Local Organization Committee Chair

Image File Program Education
200109 200202 Advanced Cancer Management Program, National Cancer Center Completed
200203 200208 Advanced Management Program, College of Business & Administraion, Seoul Nat'l University Completed
200203 200208 Advanced Program for Life Science, National Cancer Center Completed
200209 200302 Advanced Labor Management Relations Program, Korea Labor Institute Completed

Image File Editorial Board
Domestic _

Image File Awards
197300 Changhee Scholarship
197400 Honor Graduate, Seoul National University
199400 Cited in The Best Doctors in America, 2nd Edition, Woodward/White, Inc., Aiken, SC
199900 Cited in The Good Housekeeping Magazine
200000 Cited in The America's Top Doctors

의료진 소개
선생님의 논문 상세
Image File Publication (Total: 104   SCI: 69   SCI-E: 30   SSCI: 0   SCI+SCI-E+SSCI: 0   ETC: 5)
2014 SCI Clinical outcome according to the level of preexisting epidermal growth factor receptor T790M mutation in patients with lung cancer harboring sensitive epidermal growth factor receptor mutations.: Cancer. 120(14):2090~2098 (4.901)
2014 SCI Genetic variations associated with postoperative recurrence in stage I non-small-cell lung cancer: Clinical Cancer Research. 20(12):3272~3279 (8.193)
2014 SCI-E Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2011: Cancer Research and Treatment. 46(2):109~123 (2.975)
2014 SCI-E Prediction of Cancer Incidence and Mortality in Korea, 2014: Cancer Research and Treatment. 46(2):124~130 (2.975)
2014 SCI Genomic profile analysis of diffuse-type gastric cancers: Genome Biology. 15(4):R55~R55 (10.465)
2013 SCI-E Clinical significance of heterogeneity in response to retreatment with EGFR tyrosine kinase inhibitors in lung cancer patients acquiring secondary resistance to the drug: Cinical lung cancer. 15(2):145~151 (3.22)
2013 SCI-E A genome-wide association study of survival in small-cell lung cancer patients treated with irinotecan plus cisplatin chemotherapy: The Pharmacogenomics Journal. 14(1):20~27 (5.513)
2013 SCI-E The Level of Tobacco-specific Metabolite among Non-smoking Lung Cancer at Diagnosis : A Finding from Case-Control Study: Asian Pacific Journal of Cancer Prevention. 14(11):1~3 (1.271)
2013 SCI-E Levels of Tobacco-specific Metabolites among Non-smoking Lung Cancer Cases at Diagnosis: Case-control Findings: Asian Pacific journal of cancer prevention. 14(11):6591~6593 (1.271)
2013 SCI Impact of EGFR tyrosine kinase inhibitors versus chemotherapy on the development of leptomeningeal metastasis in never smokers with advanced adenocarcinoma of the lung.: Journal of neurooncology. 115(1):95~101 (3.115)
2013 SCI-E Survival of Korean Adult Cancer Patients by Stage at Diagnosis, 2006-2010: National Cancer Registry Study: Cancer Research and Treatment. 45(3):162~171 (1.962)
2013 SCI-E Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial: Lancet Oncology. 14(7):777~786 (25.117)
2013 SCI-E Prognostic Value of Gross Tumor Volume for Definitive Radiation Therapy in Patients With Locoregionally Recurrent Non-Small-Cell Lung Cancer After Surgical Resection: Clinical lung cancer. 14(4):399~406 (2.038)
2013 SCI-E Pathway-Based Analysis Using Genome-wide Association Data from a Korean Non-Small Cell Lung Cancer Study: PLoS One. 8(6):e65396~e65396 (3.73)
2013 SCI Analysis of treatment outcomes of intraventricular chemotherapy in 105 patients for leptomeningeal carcinomatosis from non-small-cell lung cancer.: Journal of thoracic oncology. 8(5):599~605 (4.473)
2013 SCI-E Prediction of Cancer Incidence and Mortality in Korea, 2013: Cancer Research and Treatment. 45(1):15~21 (1.962)
2013 SCI-E Cancer Statistics in Korea: Incidence, Mortality, Survival and Prevalence in 2010: Cancer Research and Treatment. 45(1):1~14 (1.962)
2013 SCI-E Individualized Risk Prediction Model for Lung Cancer in Korean Men: PLOS ONE. 8(2):e54823~e54823 (3.73)
2013 SCI Prognostic implications of genetic variants in advanced non-small cell lung cancer: a genome-wide association study: Carcinogenesis. 34(2):307~313 (5.632)
2013 SCI A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer: Lung Cancer. 79(2):137~142 (3.392)
2012 SCI Early neutrophil-to-lymphocyte ratio reduction as a surrogate marker of prognosis in never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy: Journal of Cancer Research Clinical Oncology. 138(12):2009~2016 (2.558)
2012 SCI A randomized phase II study of irinotecan plus cisplatin versus irinotecan plus capecitabine with or without isosorbide-5-mononitrate in advanced non-small cell lung cancer: Annals of Oncology. 23(11):2925~2930 (6.425)
2012 SCI The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non-small cell lung cancer: The Journal of Thoracic and Cardiovascular Surgery. 144(4):794~807 (3.406)
2012 SCI Ventriculolumbar Perfusion Chemotherapy for the Treatment of Leptomeningeal Carcinomatosis: A Phase I Study With Pharmacokinetic Data.: American journal of clinical oncology. Online:Published (2.005)
2012 SCI-E A genome-wide association study for irinotecan-related severe toxicities in patients with advanced non-small cell lung cancer: The Pharmacogenomics Journal. Online:Published (4.536)
2012 SCI-E Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR).: Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 30(10):1114~1121 (18.372)
2012 SCI First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.: Journal of Clinical Oncology. 30(10):1122~1128 (18.372)
2012 ETC Prediction of Cancer Incidence and Mortality in Korea, 2012: Cancer Research and Treatment. 44(1):25~31 (0)
2012 ETC Cancer Statistics in Korea: Incidence, Mortality, Survival and Prevalence in 2009: Cancer Research and Treatment. 44(1):11~24 (0)
2012 SCI FX: an RNA-Seq analysis tool on the cloud: Bioinformatics. 28(5):721~723 (5.468)
2011 SCI Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations.: Journal of clinical pathology. 64(11):947~952 (2.475)
2011 SCI Chemoport with a non-collapsible chamber as a replacement for an Ommaya reservoir in the treatment of leptomeningeal carcinomatosis: Acta Neurochirugica. 153:1971~1978 (1.329)
2011 SCI-E Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma: BMC Cancer 2011. 11:385~393 (3.153)
2011 SCI Circulating cell-free DNA in plasma of never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy.: Clin Cancer Res. 17(16):5179~87 (7.338)
2011 SCI DNA repair gene polymorphisms and benefit from gefitinib in never-smokers with lung adenocarcinoma: Cancer. 117(14):3201~3208 (5.131)
2011 SCI-E Long-term survival of cancer patients in Korea, 1993-2007: National Cancer Registry Study.: Asian Pacific journal of cancer prevention. 11(6):1459~1464 (1.24)
2011 SCI A phase 2 study of irinotecan, cisplatin, and simvastatin for untreated extensive-disease small cell lung cancer.: Cancer.. 117(10):2178~2185 (5.131)
2011 ETC Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2008.: Cancer research and treatment : official journal of Korean Cancer Association.. 43(1):1~11 (0)
2011 ETC Prediction of cancer incidence and mortality in Korea, 2011.: Cancer research and treatment : official journal of Korean Cancer Association.. 43(1):12~18 ()
2011 SCI A randomized phase II study of gefitinib plus simvastatin versus gefitinib alone in previously treated patients with advanced non-small cell lung cancer.: Clinical cancer research. 17(6):1553~1560 (7.338)
2010 SCI A Genome-wide association study reveals susceptibility variants for non-small cell lung cancer in the Korean population: Human Molecular Genetics. 19(24):4948~4954 (7.386)
2010 SCI-E Clinical characteristics of malignant pericardial effusion associated with recurrence and survival.: Cancer Research and Treatment. 42(4):210~216 (0)
2010 SCI Variation in TP63 is associated with lung adenocarcinoma susceptibility in Japanese and Korean populations: Nature Genetics. 42:893~896 (34.284)
2010 SCI Cancer Statistics in Korea: Incidence, Mortality and Survival in 2006-2007: Journal of Korean Medical Science. 25:1113~1121 (0.838)
2010 SCI Erratum: Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer.: Cancer. 116(15):3749~3749 (5.418)
2010 SCI-E Association of SUMO-1 and UBC9 genotypes with tumor response in non-small cell lung cancer treated with irinotecan-based chemotherapy: The Pharmacogenomics Journal. 10(2):86~93 (4.398)
2010 SCI-E First-Line Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status.: J Thorac Oncol.. 5(3):361~368 (4.547)
2010 SCI-E Genetic Polymorphisms in the Polycomb Group Gene EZH2 and the Risk of Lung Cancer: Journal of Thoracic Oncology. 5:10~16 (4.547)
2010 SCI Preschool children and their mothers are more exposed to paternal smoking at home than school children and their mothers: Clinica Chimica Acta(상위20#이내 학술지임). 411(1-2):72~76 (2.535)
2009 SCI Cancer Statistics in Korea: Incidence, Mortality and Survival in 2005: Journal of Korean Medical Science. 24:995~1003 (0.843)
2009 SCI Randomized, Placebo-Controlled, Phase Ⅱ Study of Sequential Erlotinib and Chemotherapy As First-Line Treatment for Advanced Non-Small Cell Lung Cancer: JOURNAL OF CLINICAL ONCOLOGY. 27(30):5080~5087 (17.157)
2009 ETC Nationwide Cancer Incidence in Korea, 2003-2005: Cancer Research and Treatment. 41(3):122~131 ()
2009 SCI A phase II study of synchronous three-dimensional conformal boost to the gross tumor volume for patients with unresectable stage III non-small-cell lung cancer: results of Koean Radiation Oncology Group 0301 study: International Journal of Radiation Oncology Biology Physics. 74(5):1397~1404 (4.639)
2009 SCI Association of CYP2A6 polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer: Pharmacogenomics. 10(7):1147~55 (3.551)
2009 SCI-E Early Prediction of Response to First-Line Therapy Using Integrated 18F-FDG PET/CT for Patients with Advanced Metastatic Non-small Cell Lung Cancer: Journal of Thoracic Oncology. 4(7):816~821 (3.508)
2009 SCI Comparison of Circulating Plasma DNA Levels between Lung Cancer Patients and Healthy Controls: Journal of Molecular Diagnostics. 11(3):182~185 (3.643)
2008 SCI Reduced local recurrence of a single brain metastasis through microscopic total resection: Journal of Neurosurgery. 110(4):730~736 (2.124)
2008 SCI Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer: Lung Cancer. Online:Published (3.455)
2008 SCI Randomized phase II study of subcutaneous amifostine versus epoetin-alfa given three times weekly during concurrent chemotherapy and hyperfractionated radiotherapy for limited-disease small cell lung cancer: Cancer. 113:1623~1631 (4.632)
2008 SCI-E Randomized phase II study of maintenance irinotecan therapy versus observation following induction chemotherapy with irinotecan and cisplatin in extensive disease small cell lung cancer: Journal of Thoracic Oncology. 3:1039~1045 (1.429)
2008 SCI Growth rates of metastatic brain tumors in nonsmall cell lung cancer: Cancer. 113:1043~1047 (4.632)
2008 SCI Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced non-small cell lung cancer: Cancer. 113:799~807 (4.632)
2008 SCI Adenocarcinoma of lung in never smoked children.: Lung Cancer. 61:266~269 (3.455)
2008 SCI Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer: Journal of Clinical Oncology. 26:3543~3551 (15.484)
2008 SCI Randomized phase 2 study of irinotecan plus cisplatin versus gemcitabine plus vinorelbine as first-line chemotherapy with second-line crossover in patients with advanced nonsmall cell lung cancer.: Cancer. 113:388~395 (4.632)
2008 SCI Primary chemotherapy for newly diagnosed nonsmall cell lung cancer patients with synchronous brain metastases compared with whole-brain radiotherapy administered first : result of a randomized pilot study: Cancer. 113:143~149 (4.632)
2008 SCI CYP1B1, CYP1A1, MPO, and GSTP1 polymorphisms and lung cancer risk in never-smoking Korean women: Lung Cancer. 60:40~46 (3.455)
2008 SCI Factors influencing attitudes to legislation banning the manufacture and sale of tobacco products.: Tobacco Control. 17:142~143 (3.277)
2008 SCI Influence of the organic anion-transporting polypeptide 1B1(OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of pationts with advanced non-small cell lung cancer: Lung Cancer. 59:69~75 (3.455)
2007 SCI A phase II trial of modified weekly irinotecan and cisplatin for chemotherapy-naive patients with metastatic or recurrent squamous cell carcinoma of the esophagus.: Cancer Chemotherapy and Pharmacology. 61:83~88 (2.568)
2007 SCI-E The hOGG1 Ser326Cys Polymorphism Is Not Associated with Colorectal Cancer Risk: Journal of Epidemiology. 17:156~160 (1.24)
2007 SCI-E Ewing's sarcoma/primitive neuroectodermal tumor (ES/PNET) of the small bowel: a rare cause of intestinal obstruction: International Journal of Colorectal Disease. 22:1137~1138 (2.006)
2007 SCI Genetic polymorphisms in the Rb-binding zinc finger gene RIZ and the risk of lung cancer: Carcinogenesis. 28:1971~1977 (5.366)
2007 SCI Combined effects of genetic polymorphisms in six selected genes on lung cancer susceptibility: Lung Cancer. 57:135~142 (3.554)
2007 SCI Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer: Cancer. 110:138~147 (4.632)
2007 SCI-E Bronchial Artery and Systemic Artery Embolization in the Management of Primary Lung Cancer Patients with Hemoptysis: Cardiovascular and interventional radiology. Online:Published (1.149)
2007 SCI-E GSTT2 promoter polymorphisms and colorectal cancer risk: BMC Cancer. 7:16~ (2.359)
2006 SCI-E The role of gefitinib treatment for Korean never-smokers with advanced or metastatic adenocarcinoma of the lung: a prospective study The role of gefitinib treatment for Korean never-smokers with advanced or metastatic adenocarcinoma of the lung: a prospective study.: Journal of Thoracic Oncology. 1:965~971 ()
2006 SCI Novel polymorphisms in the SUV39H2 histone methyltransferase and the risk of lung cancer: Carcinogenesis. 27:2217~2222 (5.108)
2006 SCI A phaseⅡ trial of docetaxel plus capecitabine in patients with previously treated non-small cell lung cancer: Japanese journal of clinical oncology. 10:1~7 (1.376)
2006 SCI Radiosensitivity enhancement by combined treatment of celecoxib and gefitinib on human lung cancer cells: Clinical Cancer Research. 12:4989~4999 (6.177)
2006 SCI A PhaseⅡstudy of irinotecan plus cisplatin for patients with advanced stage ⅢB orⅣNSCLC previously treated with nonplatinum-based chemotherapy: Cancer. 107:799~805 (4.8)
2006 SCI A pilot trial of gemcitabine and vinorelbine plus capecitabine in locally advanced or metastatic non small cell lung cancer: American Journal of Clinical Oncology. 29:143~147 (1.224)
2006 SCI Randomized phase Ⅱstudy of two opposite administration sequences of irinotecan and cisplatin in patients with advanced nonsmall cell lung carcinoma: Cancer. 106:873~880 (4.582)
2005 SCI Phase II Study of induction chemotherapy with gemcitabine and vinorelbine followed by concurrent chemoradiotherapy with oral etoposide and cisplatin in patients with inoperable stage ⅲ non-small-cell lung cancer: Int J Rad Oncol Biol Phy. 63:1037~1044 (4.297)
2005 SCI Phase II study of weekly irinotecan plus capecitabine for chemotherapy-na?ve patients with advanced non-small cell lung carcinoma: Cancer. 104:2759~2765 (4.434)
2005 SCI Relative and Absolute Risks of Cigarette Smoking on Major Histologic Types of Lung Cancer in Korean Men: Cancer Epidemiology Biomarkers & Prevention. 14:2125~2130 (4.5)
2005 SCI Relative and Absolute Risks of Cigarette Smoking on Major Histologic Types of Lung Cancer in Korean Men: Cancer Epidemiology Biomarkers & Prevention. 14:2125~2530 (4.5)
2005 SCI Role of positron emission tomography in pretreatment lymph node staging of uterine cervical cancer: A prospective surgicopathologic correlation study: European Journal of Cancer. 41:2086~2092 (3.302)
2005 SCI Role of positron emission tomography in pretreatment lymph node staging of uterine cervical cancer: A prospective surgicopathologic correlation study: European Journal of Cancer. 41:2086~2092 (3.302)
2005 SCI Dose-volumetric Parameters of Acute Esophageal Toxicity in Patients with Lung Cancer Treated with Three Dimensional Radiotherapy: International Journal of Radiation Oncology Biology Physics. 62:995~1002 (4.297)
2005 SCI Phase II Study of Irinotecan Plus Cisplatin Induction Followed by concurrent Twice-Daily Thoracic Irradiation With Etoposide Plus Cisplatin Chemotherapy for Limited-Disease Small-Cell Lung Canceer: Journal of Clinical Oncology. 23:3488~3494 (9.835)
2005 SCI Phase II Study of Irinotecan Plus Cisplatin Induction Followed by concurrent Twice-Daily Thoracic Irradiation With Etoposide Plus Cisplatin Chemotherapy for Limited-Disease Small-Cell Lung Canceer: Journal of Clinical Oncology. 23:3488~3494 (10.864)
2005 SCI Thymidine Phosphorylase Expression in Tumor Cells and Tumor Response to Capecitabine plus Docetaxel Chemotherapy in Non-Small Cell Lung Cancer: J Clin Pathol. 58:650~654 (2.966)
2005 SCI Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers: Clinical Cancer Research. 11:3032~3037 (6.511)
2005 SCI Dose-volumetric Parameters for Predicting Severe Radiation Pneumonitis after Three-dimensional Conformal Radiation Therapy for Lung cancer: Radiology. 235(1):208~224 (5.076)
2005 SCI Dose-volumetric Parameters for Predicting Severe Radiation Pneumonitis after Three-dimensional Conformal Radiation Therapy for Lung cancer: Radiology. 0:208~216 (4.815)
2005 SCI Weekly Docetaxel in Combination With Capecitabine in Patients With Metastatic Gastric Cancer: American Journal of Clinical Oncology. 28:188~194 (1.703)
2005 SCI-E Cigarette smoking and cancer incidence risk in adult men: National Health Insurance Corporation Study: Cancer Detection and Prevention. 29:15~24 (1.18)
2005 SCI-E A Phase II Study of Dose-Intensified Weekly Concomitant Administration of Cisplatin and Irinotecan in Chemonaive Patients with Extensive0Disease Small-Cell Lung Cancer: Medical Oncology. 22:281~290 (1.159)
2004 SCI Mutational analysis of OGG1, MYH, MTH1 in FAP, HNPCC and sporadic colorectal cancer patients : R154H OGG1 polymorphism is associated with sporadic colorectal cancer patients: Human Genetics. 115(6):498~503 (4.022)
2004 SCI DNA mociroarray analysis of the correlation between gene expression patterns and acquired resistance to 5-FU/cisplatin in gastric cancer: Biochemical and Biophysical Research Communications. 316:781~789 (2.904)
2003 SCI A Phase II Study of Weekly Irinotecan and capecitabine in Patients with Previously Treated Non-Small Cell Lung Cancer: Clinical Cancer Research. 9:5909~5914 (6.511)
2003 SCI A Phase II Study of Weekly Docetaxel Plus Capecitabine for Patients with Advanced Nonsmall Cell Lung Cancer: CANCER. 98:1918~1924 (3.941)